97 related articles for article (PubMed ID: 10421610)
1. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration.
Wang Y; Roy A; Sun L; Lau CE
Drug Metab Dispos; 1999 Aug; 27(8):855-9. PubMed ID: 10421610
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship.
Wright CE; Sisson TL; Fleishaker JC; Antal EJ
J Clin Pharmacol; 1997 Apr; 37(4):321-9. PubMed ID: 9115058
[TBL] [Abstract][Full Text] [Related]
3. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
4. Effect of venlafaxine on the pharmacokinetics of alprazolam.
Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
Psychopharmacol Bull; 1998; 34(2):211-9. PubMed ID: 9641003
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
[TBL] [Abstract][Full Text] [Related]
6. Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet.
Erdman K; Stypinski D; Combs M; Witt P; Stiles M; Pollock S
Pharmacotherapy; 2007 Aug; 27(8):1120-4. PubMed ID: 17655512
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers.
Glue P; Fang A; Gandelman K; Klee B
Am J Ther; 2006; 13(5):418-22. PubMed ID: 16988537
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modeling of stimulatory and sedative effects of alprazolam: timing performance deficits.
Lau CE; Heatherington AC
J Pharmacol Exp Ther; 1997 Dec; 283(3):1119-29. PubMed ID: 9399984
[TBL] [Abstract][Full Text] [Related]
9. Alprazolam kinetics following sublingual and oral administration.
Scavone JM; Greenblatt DJ; Shader RI
J Clin Psychopharmacol; 1987 Oct; 7(5):332-4. PubMed ID: 3680603
[TBL] [Abstract][Full Text] [Related]
10. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.
Palkama VJ; Ahonen J; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 1999 Jul; 66(1):33-9. PubMed ID: 10430107
[TBL] [Abstract][Full Text] [Related]
11. Different acute tolerance development to EEG, psychomotor performance and subjective assessment effects after two intermittent oral doses of alprazolam in healthy volunteers.
Barbanoj MJ; Urbano G; Antonijoan R; Ballester MR; Valle M
Neuropsychobiology; 2007; 55(3-4):203-12. PubMed ID: 17878744
[TBL] [Abstract][Full Text] [Related]
12. Absorption and enterohepatic circulation of baicalin in rats.
Xing J; Chen X; Zhong D
Life Sci; 2005 Nov; 78(2):140-6. PubMed ID: 16107266
[TBL] [Abstract][Full Text] [Related]
13. Possibility of enterohepatic recycling of ketoprofen in dogs.
Granero GE; Amidon GL
Int J Pharm; 2008 Feb; 349(1-2):166-71. PubMed ID: 17890028
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous pharmacokinetic modeling of cocaine and its metabolites, norcocaine and benzoylecgonine, after intravenous and oral administration in rats.
Sun L; Lau CE
Drug Metab Dispos; 2001 Sep; 29(9):1183-9. PubMed ID: 11502725
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine.
Hall J; Naranjo CA; Sproule BA; Herrmann N
J Clin Psychopharmacol; 2003 Aug; 23(4):349-57. PubMed ID: 12920410
[TBL] [Abstract][Full Text] [Related]
16. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats.
Choi JS; Shin SC
Int J Pharm; 2005 Mar; 292(1-2):149-56. PubMed ID: 15725561
[TBL] [Abstract][Full Text] [Related]
17. Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam.
Furukori H; Otani K; Yasui N; Kondo T; Kaneko S; Shimoyama R; Ohkubo T; Nagasaki T; Sugawara K
Neuropsychopharmacology; 1998 May; 18(5):364-9. PubMed ID: 9536449
[TBL] [Abstract][Full Text] [Related]
18. Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations.
Harrison A; Betts A; Fenner K; Beaumont K; Edgington A; Roffey S; Davis J; Comby P; Morgan P
Drug Metab Dispos; 2004 Feb; 32(2):197-204. PubMed ID: 14744941
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
[TBL] [Abstract][Full Text] [Related]
20. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
